KYNTRA BIO, INC. financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data KYNTRA BIO, INC. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	183	131	213	257	176	235	141	46.8	29.6	6.44
Cost of revenue				1.15	8.87	12.9	20.3	3.96	15.6	0.56
Gross profit				255	167	222	120	42.8	14.1	5.88
Research and development	187	197	236	209	253	387	297	266	95.7	23.5
Selling, general and administrative		51.8	63.8	135	106	124	125	86.5	49.3	27.7
General and administrative	46	51.8	63.8
Operating expenses	233	248	300	346	368
Operating income	-50	-117	-86.7	-89.3	-192	-289	-301	-323	-150	-45.9
Interest expense	10.7	9.71	11	2.88	2.4	1.08	1.44	8.1	8.25	8.76
Other non-operating income				15.5	5.55	-1.08	7.6	7.59	5.3	2.94
Pre-tax income	-58.1	-121	-86.1	-76.6	-189	-291	-295	-323	-153	-58.3
Income tax	-0.07	0.32	0.3	0.33	0.36	0.35	0.36	-0.25	-0.27	-0.09
Net income	-58.1	-121	-86.4	-77	-189	-290	-294	-284	-47.6	183
EBITDA	-44	-111	-80.1	-78.2	-180	-278	-291	-313	-148	-45.2
EPS, basic	-23.04	-41.12	-25.51	-22.05	-52.27	-77.78	-77.78	-72.33	-11.89	45.37
EPS, diluted	-23.04	-41.12	-25.51	-22.05	-52.27	-77.78	-77.78	-72.33	-11.89	45.37
Shares, basic (weighted)	2.53	2.95	3.39	3.5	3.63	3.73	3.78	3.93	4	4.04
Shares, diluted (weighted)	2.53	2.95	3.39	3.5	3.63	3.73	3.78	3.93	4	4.04

Balance sheet

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	174	674	89.3	126	678	171	156	81.6	50.5	47.9
Short-term investments	79.4	62.1	532	407	8.14	234	266	122	0	41.1
Receivables	10.4	8.45	63.7	28.5	41.9	17.4	16.3	5.12	0.48	0.22
Inventory			0	6.89	16.5	31	40.4	17.2	3.16	3.74
Other current assets	2.89	4.8	2.22	1.72	1.81	5.07	4.35	6.68	1.14	1.12
Total current assets	267	749	690	702	755	474	493	332	197	99.1
Property, plant and equipment	124	129	127	42.7	33.6	28.3	20.6	4.79	0
Lease right-of-use assets			0	1.93	2.04	91.1	79.9	64.9	0
Long-term investments		10.5	55.8	61.1	0.24				0	20.2
Other non-current assets	2.15	4.52	3.42	9.37	1.39	6.68	5.28	2.54	1.41	0.36
Total assets	470	899	881	857	827	774	610	424	215	120
Accounts payable	6.22	5.51	9.14	6.09	24.8	26.1	30.8	15.8	5.06	3.75
Accrued liabilities	50.9	63.8	66.1	83.8	118	173	220	133	62	20.2
Deferred revenue	7.99	16.7	13.8	0.49	6.55	15.9	12.7	12.7	27.3	5.31
Total current liabilities	65.1	86	89	103	163	225	274	218	133	29.2
Lease liabilities			0	0.94	0.85	88.8	79.6	65	0
Other non-current liabilities	6.19	8.05	9.99	65.4	38.8	26	6.44	2.86	0.82	0.08
Total liabilities	294	351	352	322	385	545	612	586	398	115
Paid-in capital	626	1,160	1,226	1,301	1,400	1,476	1,541	1,644	1,669	1,677
Retained earnings	-510	-631	-716	-785	-974	-1,264	-1,558	-1,842	-1,889	-1,706
Other comprehensive income	-0.96	-1.8	-2.28	-0.75	-4.5	-4.16	-5.72	-6.88	-5.73	-2.18
Shareholders' equity	156	528	509	516	422	209	-21.4	-204	-226	-30
Minority interests	19.3	19.3	19.3	19.3	19.3	20	20
Total equity	135	548	528	535	441	229	-1.48	-184	-205	-17
Total liabilities and equity	470	899	881	857	827	774	610	424	215	120
Shares outstanding	2.57	3.33	3.45	3.54	3.69	3.75	3.8	3.99	4.04	4.05

Cash flow statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	-58.1	-121	-86.4	-77	-189	-290	-294	-284	-47.6	183
Depreciation and amortization	6.04	6.1	6.56	11.1	11.7	10.2	10	9.52	2.65	0.71
Stock-based compensation	32.1	37.5	52.1	66.3	72.7	71.2	65.6	50.8	25.2	6.58
Deferred income tax	-0.21	0	0	0	0	0	0	0	0	0
Change in receivables	4.96	2	-55.2	35.2	-12	25.2	0.77	3.43	-6.74	-2.54
Change in inventory		0	0	-6.89	-9.18	-14.2	-11	-1.7	22.3	5.36
Change in payables	-0.3	-0.71	3.63	-3.05	17.7	0.81	5.91	-15.5	14.5	-27.7
Cash from operations	7.11	-66.5	-76.1	-78.7	81.6	-82.2	-146	-315	-138	-4.77
Capital expenditures	-1.25	-8.5	-8.02	-5.76	-3.99	-5.19	-3.74	-2.52	-0.27	-0.04
Purchases of investments				-411	-8.19	-484	-164	-252	-8.63	-61.2
Sales and maturities of investments	12.6	57.4	54.4	537	457	83.1	284	401	134	0
Cash from investing	6.62	69.9	-522	120	452	-427	89.1	154	126	35.4
Debt repaid									0	-75
Stock issued	9.88	34.9	29.8	20.8	37.8	12.7	4.18	3.73	0.14	0
Cash from financing	6.74	496	13.9	-4.3	13.3	-0.56	46.8	123	-0.26	-86
Net change in cash	20.5	500	-584	37	552	-507	-15.5	-42	-11.5	-54.3
Free cash flow	5.86	-75	-84.2	-84.5	77.6	-87.4	-150	-318	-138	-4.81
Interest paid	0.3	0.26	0.22	0.17	0.14	0.09	0.1	6.38	16.2	7.83
Income taxes paid									0	0

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $6.94 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	6.3%	Gross profit / revenue.
Operating margin	-1,090.0%	Operating income / revenue.
EBITDA margin	-1,086.0%	EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin	-669.6%	Pre-tax income / revenue.
Net margin	3,968.0%	Net income / revenue.
FCF margin	-824.4%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	-824.2%	Cash from operations / revenue.
Return on assets (ROA)	181.2%	Net income / average total assets.
R&D / revenue	495.2%	Research and development expense / revenue.
SG&A / revenue	599.4%	Selling, general and administrative expense / revenue.
Stock-based pay / revenue	86.3%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	0.2%	Capital expenditures / revenue.
D&A / revenue	4.0%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	-78.3%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	-64.2%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	-48.4%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	-58.2%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	-63.4%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	-48.8%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	-44.3%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	-41.9%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	-32.1%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	1.0%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	2.3%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	2.2%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	2.69x	Current assets / current liabilities.
Quick ratio	2.54x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	2.53x	(Cash + short-term investments) / current liabilities.
Liabilities / assets	108.1%	Total liabilities / total assets.
Interest coverage	-5.42x	Operating income / interest expense.
Working capital	$60.8M	Current assets - current liabilities.
Tangible book value	-$30.1M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	0.05x	Revenue / average total assets.
Inventory turnover	1.28x	Cost of revenue / average inventory.
Days inventory	285 days	365 x average inventory / cost of revenue.
Receivables turnover	13.3x	Revenue / average receivables.
Days sales outstanding	27 days	365 x average receivables / revenue.
Days payables	633 days	365 x average accounts payable / cost of revenue.
Cash conversion cycle	-321 days	Days inventory + days sales outstanding - days payables.
FCF conversion	-20.8%	Free cash flow / net income, when net income is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	$45.25	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$1.14	Revenue / diluted weighted shares.
FCF per share	-$9.40	Free cash flow / diluted weighted shares.
Operating cash flow per share	-$9.40	Cash from operations / diluted weighted shares.
Book value per share	-$7.44	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	-$7.44	Tangible book value / shares outstanding.
Cash per share	$22.55	(Cash + short-term investments) / shares outstanding.

Valuation

Metric	Value	How it is calculated
Market cap	$28.1M	Share price x shares outstanding.
Enterprise value	-$63.2M	Market cap + total debt - cash - short-term investments.
P/E	0.15x	Market cap / net income. Only when net income is positive.
P/S	6.09x	Market cap / revenue.
FCF yield	-135.4%	Free cash flow / market cap.
Earnings yield	651.9%	Net income / market cap (the inverse of P/E).

What was KYNTRA BIO, INC.'s revenue in fiscal 2025?

KYNTRA BIO, INC. reported revenue of $6.4M for fiscal 2025, 78.3% lower than the year before.

Was KYNTRA BIO, INC. profitable in fiscal 2025?

Yes. Net income was $183.5M, a net margin of 2,848.6%.

How much free cash flow did KYNTRA BIO, INC. generate in fiscal 2025?

Cash from operations of $4.8M minus capital expenditures of $38.0K left free cash flow of -$4.8M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to KYNTRA BIO, INC.